Monte Rosa Therapeutics

Monte Rosa Therapeutics

Biotechnology, 645 Summer St Ste 102, Boston, Massachusetts, 02210, United States, 51-200 Employees

monterosatx.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 61********

Who is MONTE ROSA THERAPEUTICS

Small molecule protein degraders are set to reshape the way by which diseases will be treated. Our rational approach in targeting disease-causing proteins for degradation will deliver pio...

Read More

map
  • 645 Summer St Ste 102, Boston, Massachusetts, 02210, United States Headquarters: 645 Summer St Ste 102, Boston, Massachusetts, 02210, United States
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $10 Million to $25 Million

industries-icon Industry: Biotechnology

SIC SIC Code: 1731

checked-icon Does something look wrong? Fix it. | View contact records from MONTE ROSA THERAPEUTICS

Monte Rosa Therapeutics Org Chart and Mapping

Employees

Jennifer Champoux

Chief People and Operations Officer

Chris King

VP of Nonclinical Development & Clinical Pharmacology

Sue Kim

Associate Director, Operations

Filip Janku

Chief Medical Officer

Mackenzie Barber

Senior Research Associate I, Biochemistry

Philip Nickson

SVP and General Counsel

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Monte Rosa Therapeutics

Answer: Monte Rosa Therapeutics's headquarters are located at 645 Summer St Ste 102, Boston, Massachusetts, 02210, United States

Answer: Monte Rosa Therapeutics's phone number is 61********

Answer: Monte Rosa Therapeutics's official website is https://monterosatx.com

Answer: Monte Rosa Therapeutics's revenue is $10 Million to $25 Million

Answer: Monte Rosa Therapeutics's SIC: 1731

Answer: Monte Rosa Therapeutics has 51-200 employees

Answer: Monte Rosa Therapeutics is in Biotechnology

Answer: Monte Rosa Therapeutics contact info: Phone number: 61******** Website: https://monterosatx.com

Answer: Small molecule protein degraders are set to reshape the way by which diseases will be treated. Our rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond. Headquartered in Boston with additional laboratory facilities in Basel, Monte Rosa Therapeutics is a private company launched in 2020. Initially seeded by Versant Ventures and incubated at Ridgeline Discovery in Basel, and The Institute of Cancer Research in London, Monte Rosa has raised $32.5 million from Versant and New Enterprise Associates. Academic co-founders are Prof. Raj Chopra and Prof. Ian Collins of The Institute for Cancer Research, UK.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access